{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:38:53Z","timestamp":1792143533288,"version":"4.4.0"},"reference-count":86,"publisher":"Harborside Press, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Novel targeted therapies (small molecule inhibitors, antibody\u2013drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed\/refractory B-cell lymphomas. Bruton\u2019s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed\/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed\/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.<\/jats:p>","DOI":"10.6004\/jnccn.2023.0057","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T20:28:54Z","timestamp":1699388934000},"page":"1118-1131","source":"Crossref","is-referenced-by-count":130,"title":["NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023"],"prefix":"10.6004","volume":"21","author":[{"given":"Andrew D.","family":"Zelenetz","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babis","family":"Andreadis","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Elizabeth","family":"Budde","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Chang","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Christian","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"DeVos","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saad","family":"Hamid","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Karimi","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"King","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Krivacic","sequence":"additional","affiliation":[{"name":"Consultant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Lim","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Messmer","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Narkhede","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rabinovitch","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Reid","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder","family":"Saeed","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tuscano","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Sundar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Leukemia","first-page":"1720","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I,  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 2022;36:1720\u20131748."},{"key":"B2","series-title":"Blood","first-page":"1229","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo E","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR,  The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229\u20131253."},{"key":"B3","series-title":"Cancer Res","first-page":"5307","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro A","year":"2012","unstructured":"Navarro A, Clot G, Royo C,  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72:5307\u20135316."},{"key":"B4","series-title":"Blood","first-page":"2722","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!","volume":"132","author":"Dreyling M","year":"2018","unstructured":"Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 2018;132:2722\u20132729."},{"key":"B5","series-title":"Cancer Res","first-page":"1408","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez V","year":"2010","unstructured":"Fern\u00e0ndez V, Salamero O, Espinet B,  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408\u20131418."},{"key":"B6","series-title":"Haematologica","first-page":"1121","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka SL","year":"2011","unstructured":"Ondrejka SL, Lai R, Smith SD,  Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121\u20131127."},{"key":"B7","series-title":"Blood","first-page":"1903","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund CW","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW,  TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017;130:1903\u20131910."},{"key":"B8","series-title":"Br J Haematol","first-page":"e103","article-title":"A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma","volume":"191","author":"Obr A","year":"2020","unstructured":"Obr A, Klener P, Furst T,  A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol 2020;191:e103\u2013106."},{"key":"B9","series-title":"Haematologica","first-page":"1604","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero S","year":"2020","unstructured":"Ferrero S, Rossi D, Rinaldi A,  KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica 2020;105:1604\u20131612."},{"key":"B10","series-title":"Intern Med J","first-page":"1286","article-title":"Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre","volume":"52","author":"Tam CS","year":"2022","unstructured":"Tam CS, Gregory GP, Ku M,  Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre. Intern Med J 2022;52:1286\u20131287."},{"key":"B11","series-title":"Ann Oncol","first-page":"2323","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"26","author":"Graf SA","year":"2015","unstructured":"Graf SA, Stevenson PA, Holmberg LA,  Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26:2323\u20132328."},{"key":"B12","series-title":"N Engl J Med","first-page":"1250","article-title":"Rituximab after autologous stem cell transplantation in mantle cell lymphoma","volume":"377","author":"Le Gouill S","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L,  Rituximab after autologous stem cell transplantation in mantle cell lymphoma. N Engl J Med 2017;377:1250\u20131260."},{"key":"B13","series-title":"Am J Hematol","first-page":"E50","article-title":"Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation","volume":"94","author":"Klener P","year":"2019","unstructured":"Klener P, Salek D, Pytlik R,  Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol 2019;94:E50\u201353."},{"key":"B14","series-title":"J Clin Oncol","first-page":"248","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial","volume":"38","author":"Kluin-Nelemans HC","year":"2020","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O,  Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial. J Clin Oncol 2020;38:248\u2013256."},{"key":"B15","series-title":"J Clin Oncol","first-page":"479","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle Cell Lymphoma Network","volume":"41","author":"Hermine O","year":"2023","unstructured":"Hermine O, Jiang L, Walewski J,  High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle Cell Lymphoma Network. J Clin Oncol 2023;41:479\u2013484."},{"key":"B16","series-title":"Blood","first-page":"1","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized Triangle Trial by the European MCL Network","volume":"140","author":"Dreyling M","year":"2022","unstructured":"Dreyling M, Doorduijn JK, Gine E,  Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized Triangle Trial by the European MCL Network. Blood 2022;140(Suppl 1):1\u20133."},{"key":"B17","series-title":"J Clin Oncol","first-page":"3441","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P,  Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441\u20133452."},{"key":"B18","series-title":"N Engl J Med","first-page":"319","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown JR","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P,  Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319\u2013332."},{"key":"B19","series-title":"N Engl J Med","first-page":"2482","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang ML","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M,  Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386:2482\u20132494."},{"key":"B20","series-title":"Cancer","first-page":"2630","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri IF","year":"2003","unstructured":"Khouri IF, Saliba RM, Okoroji GJ,  Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003;98:2630\u20132635."},{"key":"B21","series-title":"Blood","first-page":"2677","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling M","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E,  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677\u20132684."},{"key":"B22","series-title":"Lancet Haematol","first-page":"e648","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner AK","year":"2021","unstructured":"Zoellner AK, Unterhalt M, Stilgenbauer S,  Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2021;8:e648\u2013657."},{"key":"B23","series-title":"Cancer","first-page":"1434","article-title":"Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"104","author":"Thieblemont C","year":"2005","unstructured":"Thieblemont C, Antal D, Lacotte-Thierry L,  Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005;104:1434\u20131441."},{"key":"B24","series-title":"Leuk Lymphoma","first-page":"1062","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume":"49","author":"Till BG","year":"2008","unstructured":"Till BG, Gooley TA, Crawford N,  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49:1062\u20131073."},{"key":"B25","series-title":"Br J Haematol","first-page":"524","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"van\u2019t Veer MB","year":"2009","unstructured":"van\u2019t Veer MB, de Jong D, MacKenzie M,  High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524\u2013530."},{"key":"B26","series-title":"Eur J Haematol","first-page":"220","article-title":"Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation","volume":"111","author":"Metzner B","year":"2023","unstructured":"Metzner B, M\u00fcller TH, Casper J,  Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol 2023;111:220\u2013228."},{"key":"B27","series-title":"Leukemia","first-page":"2762","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang M","year":"2019","unstructured":"Wang M, Rule S, Zinzani PL,  Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33:2762\u20132766."},{"key":"B28","series-title":"Blood Adv","first-page":"2577","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam CS","year":"2021","unstructured":"Tam CS, Opat S, Simpson D,  Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021;5:2577\u20132585."},{"key":"B29","series-title":"Lancet Oncol","first-page":"716","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang M","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N,  Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol 2012;13:716\u2013723."},{"key":"B30","series-title":"J Hematol Oncol","first-page":"171","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang M","year":"2017","unstructured":"Wang M, Schuster SJ, Phillips T,  Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004). J Hematol Oncol 2017;10:171."},{"key":"B31","series-title":"N Engl J Med","first-page":"507","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang ML","year":"2013","unstructured":"Wang ML, Rule S, Martin P,  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507\u2013516."},{"key":"B32","series-title":"Blood","first-page":"739","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang ML","year":"2015","unstructured":"Wang ML, Blum KA, Martin P,  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739\u2013745."},{"key":"B33","series-title":"Br J Haematol","first-page":"404","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain P","year":"2018","unstructured":"Jain P, Romaguera J, Srour SA,  Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL). Br J Haematol 2018;182:404\u2013411."},{"key":"B34","series-title":"Leukemia","first-page":"1799","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule S","year":"2018","unstructured":"Rule S, Jurczak W, Jerkeman M,  Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018;32:1799\u20131803."},{"key":"B35","series-title":"Br J Haematol","first-page":"290","article-title":"Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients","volume":"193","author":"McCulloch R","year":"2021","unstructured":"McCulloch R, Lewis D, Crosbie N,  Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol 2021;193:290\u2013298."},{"key":"B36","series-title":"Haematologica","first-page":"e68","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre TA","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S,  Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019;104:e68\u201371."},{"key":"B37","series-title":"Am J Hematol","first-page":"623","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) \u2014 outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao S","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L,  Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) \u2014 outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 2020;95:623\u2013629."},{"key":"B38","series-title":"Blood Adv","first-page":"1553","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan FT","year":"2019","unstructured":"Awan FT, Schuh A, Brown JR,  Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019;3:1553\u20131562."},{"key":"B39","series-title":"Haematologica","first-page":"2364","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers KA","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN,  Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica 2021;106:2364\u20132373."},{"key":"B40","series-title":"Lancet Haematol","first-page":"e35","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman M","year":"2023","unstructured":"Shadman M, Flinn IW, Levy MY,  Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol 2023;10:e35\u201345."},{"key":"B41","series-title":"J Clin Oncol","first-page":"555","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang M","year":"2023","unstructured":"Wang M, Munoz J, Goy A,  Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 2023;41:555\u2013567."},{"key":"B42","series-title":"Blood","first-page":"1559","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin P","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP,  Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016;127:1559\u20131563."},{"key":"B43","series-title":"Am J Hematol","first-page":"E137","article-title":"Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib","volume":"96","author":"Jain P","year":"2021","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S,  Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 2021;96:E137\u2013140."},{"key":"B44","series-title":"Br J Haematol","first-page":"749","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess G","year":"2022","unstructured":"Hess G, Dreyling M, Oberic L,  Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol 2022;202:749\u2013759."},{"key":"B45","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"S394","article-title":"MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1\/2 BRUIN study","volume":"22","author":"Cohen JB","year":"2022","unstructured":"Cohen JB, Shah NN, Alencar AJ,  MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1\/2 BRUIN study. Clin Lymphoma Myeloma Leuk 2022;22(Suppl 2):S394\u2013395."},{"key":"B46","series-title":"Blood","article-title":"Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed\/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1\/2 BRUIN study","volume":"140","author":"Wang ML","year":"2022","unstructured":"Wang ML, Shah NN, Jurczak W,  Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed\/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1\/2 BRUIN study. Blood 2022;140(Suppl 1):Abstract 623."},{"key":"B47","series-title":"Transplant Cell Ther","first-page":"720","article-title":"American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma","volume":"27","author":"Munshi PN","year":"2021","unstructured":"Munshi PN, Hamadani M, Kumar A,  American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma. Transplant Cell Ther 2021;27:720\u2013728."},{"key":"B48","series-title":"Blood","article-title":"3-year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"140","author":"Neelapu SS","year":"2022","unstructured":"Neelapu SS, Chavez J, Sehgal AR,  3-year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). Blood 2022;140(Suppl 1):Abstract 705."},{"key":"B49","series-title":"Nat Med","first-page":"325","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler NH","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M,  Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325\u2013332."},{"key":"B50","series-title":"Lancet Oncol","first-page":"1433","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser F","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A,  Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433\u20131442."},{"key":"B51","series-title":"Am J Hematol","first-page":"362","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling M","year":"2020","unstructured":"Dreyling M, Santoro A, Mollica L,  Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 2020;95:362\u2013371."},{"key":"B52","series-title":"J Clin Oncol","first-page":"912","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn IW","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM,  DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37:912\u2013922."},{"key":"B53","series-title":"N Engl J Med","first-page":"1008","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal AK","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S,  PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008\u20131018."},{"key":"B54","series-title":"Blood","first-page":"3037","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal AK","year":"2017","unstructured":"Gopal AK, Kahl BS, Flowers CR,  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 2017;129:3037\u20133039."},{"key":"B55","series-title":"J Clin Oncol","first-page":"1609","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler NH","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W,  Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39:1609\u20131618."},{"key":"B56","series-title":"Lancet Oncol","first-page":"563","article-title":"The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint","volume":"23","author":"Richardson NC","year":"2022","unstructured":"Richardson NC, Kasamon Y, Pazdur R,  The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol 2022;23:563\u2013566."},{"key":"B57","series-title":"N Engl J Med","first-page":"1540","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip T","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A,  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 1995;333:1540\u20131545."},{"key":"B58","series-title":"J Clin Oncol","first-page":"406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"19","author":"Vose JM","year":"2001","unstructured":"Vose JM, Zhang MJ, Rowlings PA,  Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406\u2013413."},{"key":"B59","series-title":"Ann Oncol","first-page":"140","article-title":"High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group","volume":"14","author":"Caballero MD","year":"2003","unstructured":"Caballero MD, P\u00e9rez-Sim\u00f3n JA, Iriondo A,  High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14:140\u2013151."},{"key":"B60","series-title":"Ann Oncol","first-page":"1504","article-title":"Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin\u2019s lymphoma not achieving complete response after induction chemotherapy: the GEL\/TAMO experience","volume":"15","author":"Rodriguez J","year":"2004","unstructured":"Rodriguez J, Caballero MD, Gutierrez A,  Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin\u2019s lymphoma not achieving complete response after induction chemotherapy: the GEL\/TAMO experience. Ann Oncol 2004;15:1504\u20131509."},{"key":"B61","series-title":"Blood","first-page":"1416","article-title":"Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?","volume":"137","author":"Shah NN","year":"2021","unstructured":"Shah NN, Ahn KW, Litovich C,  Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood 2021;137:1416\u20131423."},{"key":"B62","series-title":"Biol Blood Marrow Transplant","first-page":"788","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry","volume":"18","author":"Mounier N","year":"2012","unstructured":"Mounier N, Canals C, Gisselbrecht C,  High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012;18:788\u2013793."},{"key":"B63","series-title":"Blood","first-page":"1330","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman M","year":"2022","unstructured":"Shadman M, Pasquini M, Ahn KW,  Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood 2022;139:1330\u20131339."},{"key":"B64","series-title":"J Clin Oncol","first-page":"155","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn LH","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR,  Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38:155\u2013165."},{"key":"B65","series-title":"Lancet Oncol","first-page":"978","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles G","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez-Barca E,  Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978\u2013988."},{"key":"B66","series-title":"Lancet Oncol","first-page":"790","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi PF","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP,  Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22:790\u2013800."},{"key":"B67","series-title":"Lancet Haematol","first-page":"e511","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda N","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F,  Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7:e511\u2013522."},{"key":"B68","series-title":"Bone Marrow Transplant","first-page":"51","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study","volume":"51","author":"Van Den Neste E","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N,  Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant 2016;51:51\u201357."},{"key":"B69","series-title":"Blood","first-page":"1800","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump M","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U,  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800\u20131808."},{"key":"B70","series-title":"Cancer","first-page":"293","article-title":"Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure","volume":"126","author":"Ayers EC","year":"2020","unstructured":"Ayers EC, Li S, Medeiros LJ,  Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 2020;126:293\u2013303."},{"key":"B71","series-title":"Blood","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu SS","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A,  Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141:2307\u20132315."},{"key":"B72","series-title":"Lancet Oncol","first-page":"1403","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster SJ","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P,  Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:1403\u20131415."},{"key":"B73","series-title":"Lancet","first-page":"839","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson JS","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI,  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839\u2013852."},{"key":"B74","series-title":"Lancet Oncol","first-page":"1066","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal A","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA,  Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 2022;23:1066\u20131077."},{"key":"B75","series-title":"N Engl J Med","first-page":"640","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke FL","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA,  Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640\u2013654."},{"key":"B76","series-title":"Blood","first-page":"1675","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson JS","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J,  Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023;141:1675\u20131684."},{"key":"B77","series-title":"Biol Blood Marrow Transplant","first-page":"e344","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne M","year":"2019","unstructured":"Byrne M, Oluwole OO, Savani B,  Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e344\u2013351."},{"key":"B78","series-title":"Am J Hematol","first-page":"E209","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow VA","year":"2019","unstructured":"Chow VA, Gopal AK, Maloney DG,  Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol 2019;94:E209\u2013213."},{"key":"B79","series-title":"Lancet Oncol","first-page":"1055","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde LE","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M,  Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23:1055\u20131065."},{"key":"B80","series-title":"Blood","article-title":"Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study","volume":"140","author":"Bartlett NL","year":"2022","unstructured":"Bartlett NL, Sehn LH, Matasar MJ,  Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study. Blood 2022;140(Suppl 1):Abstract 623."},{"key":"B81","series-title":"J Clin Oncol","first-page":"2238","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont C","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H,  Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol 2023;41:2238\u20132247."},{"key":"B82","series-title":"N Engl J Med","first-page":"2220","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson MJ","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F,  Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387:2220\u20132231."},{"key":"B83","series-title":"J Clin Oncol","article-title":"Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study","volume":"41","author":"Falchi L","year":"2023","unstructured":"Falchi L, Carlo-Stella C, Morschhauser F,  Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. J Clin Oncol 2023;41(Suppl):Abstract 7550."},{"key":"B84","series-title":"Biol Blood Marrow Transplant","first-page":"625","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL,  ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625\u2013638."},{"key":"B85","series-title":"Nat Rev Clin Oncol","first-page":"47","article-title":"Chimeric antigen receptor T-cell therapy \u2014assessment and management of toxicities","volume":"15","author":"Neelapu SS","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P,  Chimeric antigen receptor T-cell therapy \u2014assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47\u201362."},{"key":"B86","series-title":"Blood","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain T","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood 2023;141:2460\u20132469."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/11\/article-p1118.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/11\/article-p1118.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/11\/article-p1118.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T20:28:54Z","timestamp":1699388934000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/11\/article-p1118.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":86,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.0057","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}